Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

ly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements including without limitation statements related to the potential safety, efficacy and commercial potential of voreloxin; planned additional clinical testing and development efforts for voreloxin; and the timing of enrollment in the ongoing clinical trials of voreloxin. Words such as "promising," "effort," "suggest," "appears," "encouraging," designed," "look forward," "estimate," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia ... Machine,” is still strongly maintaining her firm’s success in the hair care and ... her upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, ...
(Date:9/1/2015)... Melbourne, Florida (PRWEB) , ... ... ... Association of Professional Background Screeners (NAPBS®) has announced that Edge Information ... audit conducted by the Background Screening Credentialing Council (BSCC). , “Achieving ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, ... its inception more than 35 years ago. A pilot program begun by the company ... and, not just those intent on pursuing careers in these fields. The program is ...
(Date:9/1/2015)... ME (PRWEB) , ... September 01, 2015 , ... Royal ... large, new study that followed men and women for 19 years and found that, ... who did not take multivitamins. , The report is part of the September 2015 ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... Children recovering,from orthopaedic surgery feel less pain and ... a small pouch that delivers local anesthetic agents ... in adults,doctors at The Children,s Hospital of Philadelphia ... published in the November 2007 issue of the ...
... BD (Becton,Dickinson and Company) (NYSE: BDX ) announced ... Board of Directors, effective November 19, 2007. Ms. ... Executive,Officer of the Federal Reserve Bank of Boston, one ... of Governors in Washington, D.C. form,the Federal Reserve System. ...
... Del., Nov. 2 Staff and board,members of Delaware ... Lloyd, MSN, RN, for 20 years of service at ... has guided Delaware Hospice from a fledgling,grassroots organization to ... community support with quality and compassion., In 1987, ...
... lead to new treatments, researchers say , , FRIDAY, Nov. 2 ... mechanism that makes blood pressure go up or down -- ... that affects at least 50 million Americans. , A report ... is the latest in a series of studies on ...
... Rowland, Common, Romeo and Lyfe ... ... national HIV/AIDS public information campaign with the,Kaiser Family Foundation, Rap-It-Up teamed up ... THAT? RAP-IT-UP SEX,QUIZ" slated to premiere on Monday, November 5 at 7:30 ...
... full healthcare benefits for all Egyptians by,2011; schools to ... compete in the global economy, CAIRO, Egypt, Nov. ... major issues on the agenda at,the National Democratic Party ... at ways to accelerate development of a healthcare program,that ...
Cached Medicine News:Health News:Anesthesia Pouch Allows Children to Go Home Sooner After Surgery 2Health News:Anesthesia Pouch Allows Children to Go Home Sooner After Surgery 3Health News:BD Board of Directors Elects Cathy E. Minehan 2Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 2Health News:Delaware Hospice Honors President and CEO Susan D. Lloyd, MSN, RN 3Health News:Study Describes Molecules That Control Blood Pressure 2Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 2Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 3Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 4Health News:Social Justice Issues Take Main Stage at Egypt's National Democratic Party Convention 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: